Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$137.83 USD
-3.33 (-2.36%)
Updated Mar 27, 2024 04:00 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Cash flow Statements
Fiscal Year End for Neurocrine Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 249.70 | 154.50 | 89.60 | 407.30 | 37.01 |
Depreciation/Amortization & Depletion | 3.70 | 16.80 | 28.20 | 30.00 | 25.80 |
Net Change from Assets/Liabilities | 28.20 | -67.40 | 16.70 | -37.90 | 0.24 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 108.30 | 235.50 | 122.00 | -170.90 | 89.00 |
Net Cash From Operating Activities | 389.90 | 339.40 | 256.50 | 228.50 | 152.05 |
Property & Equipment | -28.30 | -16.50 | -23.40 | -10.90 | -14.74 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -42.70 | 0.00 | 0.00 | 0.00 |
Investments | -438.80 | -117.90 | -106.80 | 15.00 | -196.33 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -467.10 | -177.10 | -130.20 | 4.10 | -211.07 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 65.30 | 44.70 | 27.50 | 29.10 | 27.31 |
Issuance (Repayment) of Debt | 0.00 | -279.00 | -0.10 | -186.90 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 65.30 | -234.30 | 27.40 | -157.80 | 27.31 |
Effect of Exchange Rate Changes | 0.30 | -1.30 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -11.60 | -73.30 | 153.70 | 74.80 | -31.71 |
Cash at Beginning of Period | 270.70 | 344.00 | 190.30 | 115.50 | 147.19 |
Cash at End of Period | 259.10 | 270.70 | 344.00 | 190.30 | 115.49 |
Diluted Net EPS | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 |
Fiscal Year End for Neurocrine Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 249.70 | 102.00 | 18.90 | -76.60 | 154.50 |
Depreciation/Amortization & Depletion | 3.70 | 16.20 | 10.50 | 5.20 | 16.80 |
Net Change from Assets/Liabilities | 28.20 | 81.90 | 35.90 | -57.50 | -67.40 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 108.30 | 66.30 | -10.90 | 3.70 | 235.50 |
Net Cash From Operating Activities | 389.90 | 266.40 | 54.40 | -125.20 | 339.40 |
Property & Equipment | -28.30 | -22.90 | -15.30 | -8.50 | -16.50 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | -42.70 |
Investments | -438.80 | -242.40 | -152.70 | -33.60 | -117.90 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -467.10 | -265.30 | -168.00 | -42.10 | -177.10 |
Uses of Funds
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 65.30 | 29.90 | 11.10 | 8.20 | 44.70 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | -279.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 65.30 | 29.90 | 11.10 | 8.20 | -234.30 |
Effect of Exchange Rate Changes | 0.30 | 0.00 | 0.00 | 0.00 | -1.30 |
Net Change In Cash & Equivalents | -11.60 | 31.00 | -102.50 | -159.10 | -73.30 |
Cash at Beginning of Period | 270.70 | 270.70 | 270.70 | 270.70 | 344.00 |
Cash at End of Period | 259.10 | 301.70 | 168.20 | 111.60 | 270.70 |
Diluted Net EPS | 1.49 | 0.82 | 0.95 | -0.79 | 0.91 |